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Chronic subclinical prion disease induced by low-dose inoculum
Abstract
We have compared the transmission characteristics of the two mouse-adapted scrapie isolates, ME7 and
Rocky Mountain Laboratory (RML), in tga20 mice. These mice express elevated levels of PrP protein
compared to wild-type mice and display a relatively short disease incubation period following
intracerebral prion inoculation. Terminal prion disease in tga20 mice induced by ME7 or RML was
characterized by a distinct pattern of clinical signs and different incubation times. High-dose RML
inoculated intracerebrally into tga20 mice induced the most rapid onset of clinical signs, with mice
succumbing to terminal disease after only 58 +/- 3 days. In contrast, high-dose ME7 gave a mean time to
terminal disease of 74 +/- 0 days. Histological examination of brain sections from prion-inoculated
tga20 mice at terminal disease showed that ME7 gave rise to a more general and extensive pattern of
vacuolation than RML. Low-dose inoculum failed to induce terminal disease but did cause preclinical
symptoms, including the appearance of reversible clinical signs. Some mice oscillated between showing
no clinical signs and early clinical signs for many months but never progressed to terminal disease.
Brain tissue from these mice with chronic subclinical prion disease, sacrificed at >200 days
postinoculation, contained high levels of infectivity and showed the presence of PrP(Sc). Parallel
analysis of brain tissue from mice with terminal disease showed similar levels of infectivity and
detectable PrP(Sc). These results show that high levels of infectivity and the presence of the abnormal
isomer of PrP can be detected in mice with subclinical disease following low-dose prion inoculation.
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We have compared the transmission characteristics of the two mouse-adapted scrapie isolates, ME7 and
Rocky Mountain Laboratory (RML), in tga20 mice. These mice express elevated levels of PrP protein compared
to wild-type mice and display a relatively short disease incubation period following intracerebral prion
inoculation. Terminal prion disease in tga20 mice induced by ME7 or RML was characterized by a distinct
pattern of clinical signs and different incubation times. High-dose RML inoculated intracerebrally into tga20
mice induced the most rapid onset of clinical signs, with mice succumbing to terminal disease after only 58 
3 days. In contrast, high-dose ME7 gave a mean time to terminal disease of 74  0 days. Histological
examination of brain sections from prion-inoculated tga20 mice at terminal disease showed that ME7 gave rise
to a more general and extensive pattern of vacuolation than RML. Low-dose inoculum failed to induce terminal
disease but did cause preclinical symptoms, including the appearance of reversible clinical signs. Some mice
oscillated between showing no clinical signs and early clinical signs for many months but never progressed to
terminal disease. Brain tissue from these mice with chronic subclinical prion disease, sacrificed at >200 days
postinoculation, contained high levels of infectivity and showed the presence of PrPSc. Parallel analysis of brain
tissue from mice with terminal disease showed similar levels of infectivity and detectable PrPSc. These results
show that high levels of infectivity and the presence of the abnormal isomer of PrP can be detected in mice with
subclinical disease following low-dose prion inoculation.
Prion diseases such as scrapie of sheep, bovine spongiform
encephalopathy (BSE) of cattle, and Creutzfeldt-Jakob disease
(CJD) of humans are neurodegenerative transmissible dis-
eases. The protein-only hypothesis (21, 35) predicts that the
transmissible prion agent consists solely of proteinacious ma-
terial. During prion disease, PrPSc, an abnormal isomer of a
host protein termed PrPc, accumulates in proteolytic-resistant
aggregates. As a consequence, it is proposed that PrPSc forms
part or all of the transmissible prion agent and that it is this
abnormal isomer which is responsible for the modification of
the structure of PrPc. A feature of prion disease has been the
description of distinct prion strains which have been used as
evidence for the presence of a replicating genome within the
infectious agent (4). The protein-only hypothesis predicts that
different prion strains represent different conformations of
PrPSc (38). Different prion inocula may be characterized by
several criteria, including their biological properties (33), his-
topathology (18), and variations in the pattern of PrPSc depo-
sition (22) and the length of the disease incubation period
following experimental inoculation (15).
With respect to prion diseases, the term incubation period is
usually defined as the length of time from inoculation to the
appearance of clinical signs associated with terminal disease.
The incubation period is dependent upon the species and
strain of host, the inoculum, and the route of inoculation and
is inversely related to the titer of inoculum (34, 36). During the
progression of prion disease, infectivity and PrPSc accumulate
in the central nervous system, and in lymphoid tissue following
peripheral inoculation, within a clinically silent phase. Follow-
ing a prion strain-specific incubation period, this preclinical
phase usually precipitates into clinically evident terminal dis-
ease. However, prion-infected animals that harbor infectivity
and appear grossly unaffected during their normal lifetimes
following prion inoculation have been reported. Such individ-
uals may be considered to have subclinical as opposed to pre-
clinical infection (12). There are several examples in the liter-
ature of chronic subclinical prion infections. Frigg et al. (19)
have reported immunodeficient mice with high prion and PrPSc
levels which remain asymptomatic. Race and Chesebro (37)
have shown that brain homogenates from mice inoculated with
hamster prions harbor infectivity for hamsters, while Hill et al.
(23) have demonstrated that hamster prions do indeed repli-
cate in mice without causing clinical disease. A significant
feature of all of these reports is that the resultant infectivity in
animals with subclinical disease was seen after inoculation with
a high dose of inoculum. One intriguing case of subclinical
disease has been described by Taylor et al. (39), who have
reported intermittent mild or early clinical signs in mice inoc-
ulated with low doses of ME7 prion inoculum.
The Prnpa mouse-passaged strains ME7 and Rocky Moun-
tain Laboratory (RML) are the two principal mouse inocula
which have been used to address which cell types of the im-
mune system interact with or accumulate prions following pe-
ripheral prion inoculation (3, 27, 28). These two inocula both
originate from scrapied sheep but from different tissues. RML
is derived from experimental goats previously inoculated with
the sheep scrapie brain homogenate SSBP/1 (8, 11), and ME7
is derived from the spleen of a scrapied sheep (5). Although
RML and ME7 have specific incubation periods and induce
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distinct neuropathological characteristics when inoculated into
nontransgenic (hereafter referred to as wild-type) mouse
strains, they are similar in that their peripheral accumulation is
dependent upon the presence of follicular dendritic cells (32).
However, it remains to be resolved whether these two prion
strains have subtle transmission characteristics that are mani-
fested in differences in affinity for other target cells.
Here we have used the tga20 mouse strain (16) in our initial
studies on the comparison of transmission of RML and ME7.
This strain of mouse expresses high levels of Prnpa-derived PrP
and has a relatively short incubation time for prion disease,
thereby permitting a rapid disease assessment. We have estab-
lished that tga20 mice are susceptible to both ME7 and RML
inocula, with each producing distinct transmission characteris-
tics. Significantly, we have found that low doses of either ME7
or RML induce subclinical disease in tga20 mice which is as-
sociated with high levels of infectivity and the presence of PrPSc.
Our data suggest that events other than merely prion accumu-
lation are responsible for triggering terminal prion disease.
MATERIALS AND METHODS
Mice. The tga20 mouse strain (16) was obtained from Charles Weissmann.
Mice were bred in sterile isolators and transferred to conventional animal facil-
ities for inoculation with ME7- or RML-infected brain homogenate. CD-1 Swiss
and C57BL/6 wild-type mice were purchased from Harlan UK. CD-1, C57BL/6,
and tga20 mice all express the Prnpa allelic form of the mouse PrP gene. All
regulated procedures involving experimental animals were carried out under
project and personal license authority issued in accordance with The Animals
(Scientific Procedures) Act 1986.
Genotyping of tga20 mice. The genotype of tga20 mice was verified by PCR
using genomic DNA as a substrate. Genomic DNA was isolated by phenol-
chloroform extraction from tail snip tissue previously digested in buffer compris-
ing 500 mM Tris HCl (pH 8.0), 20 mM EDTA, 1.0% sodium dodecyl sulfate, 10
mM NaCl, and 150 g of proteinase K (PK) per ml overnight at 37°C. PCR tubes
contained 1.0 U of Taq polymerase, 100 ng of substrate DNA, 1 PCR buffer,
200 M deoxynucleoside triphosphates, 0.1 nM each primer,1.5 mM MgCl2, and
10% dimethyl sulfoxide in a final volume of 25 l. PCR was carried out in a
thermal cycler for 30 cycles after an initial DNA melt of 94°C for 2 min, where
one cycle comprised denaturation at 95°C for 1 min, annealing at 55°C for 1 min,
and extension at 72°C for 1 min. The final extension was for 10 min at 72°C. PCR
products were electrophoresed through a 1.5% agarose gel and visualized by
ethidium bromide staining and UV transillumination. The primers were as fol-
lows: for PrP0/0, ATTCGCAGCGCATCGCCTTCTATCGCC; for P10 trans-
gene, GTACCCATAATCAGTGGAACAAGCCCAGC; and for both Prnp0/0
and transgene, P3-NC (CCCTCCCCCAGCCTAGACCACGA).
Intracerebral inoculations and infectivity bioassay. Mice, either male or fe-
male, at 5 to 6 weeks of age were inoculated by intracerebral injection into the
right parietal lobe at a depth of 4 to 5 mm. Serial 10-fold dilutions of either ME7
(TSE Resource Centre, Institute of Animal Health, Compton, United Kingdom)
or RML brain homogenate were inoculated as a 20-l volume diluted in phos-
phate-buffered saline (PBS) or PBS plus 5% bovine serum albumin, respectively.
RML 5.0 is derived by passage of RML 4.1 in CD-1 mice. Control tga20 mice
were mock injected with PBS or received uninfected CD-1, C57BL/6 brain
homogenate, or, subsequently, brain homogenate from these control mice. Initial
10% homogenates were made up in 0.32 M sucrose prior to serial dilution.
Inoculated mice were monitored daily for clinical signs of mouse prion disease.
The diagnosis of prion disease was based upon that of Dickinson et al. (15). Mice
were sacrificed at the point of neurological disease and dysfunction.
Histology and immunocytochemistry. Brain tissue from representative mice
for all treatment groups was fixed in buffered formalin for 24 h, inactivated for
1 h with 98% formic acid, soaked in buffered formalin for a further 72 h, and then
embedded in paraffin wax. Paraffin sections (5 m in thickness) were subjected
to conventional staining with hematoxylin and eosin. Brain sections from termi-
nally sick mice were examined histologically to confirm scrapie pathology (mi-
crovacuolation). Reactive gliosis was confirmed by immunohistochemistry for
glial fibrillary acidic protein (GFAP) diluted 1:200 (DAKO, Glostrup, Denmark)
and developed with an avidin-biotin labeling kit (Vector Labs, Peterborough,
United Kingdom).
Western blot analysis. Brain homogenates were made to 10% (wt/vol) with
either homogenate buffer (0.5% Nonidet P-40 and 0.5% sodium deoxycholate in
PBS) for RML samples or lysis buffer (0.5% Nonidet P-40, 0.5% sodium deoxy-
cholate, 100 mM NaCl, 10 mM EDTA, and 10 mM Tris HCl [pH 7.4]) for ME7
samples. Samples were treated with PK at a final concentration of 25 g/ml for
30 min at 37°C. Digestion was terminated by the addition of phenylmethylsul-
fonyl fluoride. Ten microliters for non-PK-treated samples or 15 l for PK-
treated samples (equivalent to 40 to 50 g of total protein) was loaded and
electrophoresed through a sodium dodecyl sulfate–16% polyacrylamide minigel.
Proteins were transferred to nitrocellulose membranes by semidry blotting.
Membranes were blocked with TBS-T (10 mM Tris HCl [pH 7.8], 100 mM NaCl,
0.05% Tween 20) plus 5% nonfat milk and subsequently incubated in 1% nonfat
milk in TBS-T with XN polyclonal anti-mouse PrP serum (32) (1/1,000) for 1 h,
followed by goat anti-rabbit immunoglobulin G–biotin (catalog no. B-7389;
Sigma) (1/500) and finally extravidin-horseradish peroxidase (catalog no. E-2886;
Sigma) (1/500). All dilutions of antibodies were in 1% nonfat milk in TBS-T. PrP
bands were detected by enhanced chemiluminescence.
RESULTS
Identification of tga20 mice. The tga20 mouse line was gen-
erated by Fischer et al. (16) by transgenesis of the wild-type
PrP gene into Zürich I PrP0/0. As a consequence, tga20 mice
contain50 copies of the PrP transgene and express10-fold-
higher levels of PrPc protein. The mice used here were con-
firmed as being tga20 mice by PCR using primers to detect the
wild-type PrP transgene and the Neo-PrP targeting construct
used to generate the original PrP0/0 line. Genomic DNA from
tga20 mice contained the predicted wild-type PrP and Neo-PrP
PCR products of 0.8 and 0.7 kb, respectively. Wild-type and
PrP0/0 mice contain either the 0.8- or 0.7-kb band, respectively
(data not shown).
ME7 and RML inocula induce different clinical signs of
terminal prion disease. Inoculation of tga20 mice intracere-
brally with either ME7- or RML-infected brain homogenate
resulted in mouse prion disease with clearly evident, progres-
sive clinical signs, as described in Table 1. Prion disease in-
duced by ME7 or RML normally began with similar early signs.
Mice initially displayed dull, ruffled coats and developed hy-
peractive behavior associated with jerky and uncontrollable
running movements. This was soon followed by kyphosis
(hunched posture) and a high stepping gait coupled with a
tendency to display a straight tail, held parallel to the ground.
Head twitching became prominent in both ME7- and RML-
infected mice, while those infected with RML were prone to
hold their heads to one side (usually the right) when in motion.
These early signs of prion disease were followed by neurolog-
ical indicators of dysfunction. Mice developed proprioceptive
deficits as evidenced by clasped feet when raised by the tail.
Most mice eventually became extremely lethargic and listless,
coupled with having a blank stare. The majority of mice sub-
sequently carried their tails in a C shape. This was followed by
mild ataxia which gradually became more severe, and mice
progressively displayed a rolling gait. In the late stages of
disease, tga20 mice inoculated with RML usually showed more
hyperactive behavior than those inoculated with ME7. A sig-
nificant feature of late terminal disease was that approximately
40% of the RML-infected mice developed pruritus, whereas
those inoculated with ME7 showed no signs of scratching. All
mice were sacrificed at a standard clinical end point once
terminal scrapie symptoms had been established. All mice in
individual groups reached terminal disease at very similar
times. We compared prion incubation times in males and fe-
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males to verify whether there was a sex-related difference and
to maximize the use of all of the mice from the breeding
colony. We found no significant difference in incubation times
between males and females following intracerebral inoculation
(data not shown). Control tga20 mice were inoculated with
brain homogenate from uninfected brains of either C57BL/6 or
CD-1 mice, which are the mouse strains used to passage ME7
or RML, respectively. All of the control inoculated tga20 mice
remained healthy for the duration of the experiment and did
not exhibit clinical signs at any time.
Different incubation times for ME7 and RML in tga20 mice.
ME7 and RML inocula injected intracerebrally into tga20 mice
induced prion disease with significantly different incubation
times (defined here as the time between inoculation and eu-
thanasia at terminal disease), as shown by the data in Table 2.
RML prions induced the shortest incubation time for disease
onset, and at the highest dose tested this was 58  0.6 days. At
this and other high doses of RML, the progression from initial
clinical signs to terminal disease was fairly rapid and usually
was complete within 3 to 5 days. At lower doses of RML, the
incubation time was extended and so was the time taken for
mice to display the complete range of clinical signs, which was
12 days at its maximum. The highest concentration of ME7
tested in tga20 mice showed an incubation time of 74  1.1
days for progression to terminal disease, which became more
extended with lower doses of inoculum. In contrast to RML, at
all of the doses of ME7 which induced terminal disease, pro-
gression through the complete range of clinical signs from
initial onset to terminal disease proceeded with a fairly fixed
time, typically 14 days. The incubation times for different prep-
arations of RML and ME7 in tga20 mice were fairly similar as
seen by the regression analysis lines for each inoculum plotted
using the least-squares method as described by Prusiner et al.
(36) (Fig. 1). A significant difference between ME7 and RML
was seen in the infectivity titers of each inoculum calculated us-
ing the statistical method of Karber (25). ME7 titers were con-
sistently lower than those of RML, as shown in Table 2. The
difference in the incubation period between ME7 and RML
may be due to a difference in the titer of these two inocula.
Incubation times of ME7 and RML in nontransgenic wild-
type mice. The brain homogenates used to inoculate tga20
mice were derived from terminally sick C57BL/6 or CD-1 mice
previously inoculated with ME7 or RML, respectively. The
incubation period for ME7- or RML-induced disease in tga20
mice was considerably shorter than that seen in wild-type mice,
as shown by the data in Table 3. The incubation period in
C57BL/6 mice for high-dose ME7-induced disease was 160 
5 days, which is approximately twice as long as that in tga20
mice. Similarly, the incubation period for high-dose RML in
CD-1 mice was 134  3 days, which is approximately twofold
greater than that seen in tga20 mice. Interestingly, the clinical
signs for prion-induced disease and their duration were differ-
ent for wild-type mice and tga20 mice with respect to each
inoculum. C57BL/6 mice inoculated with ME7 showed an ex-
tended range of clinical signs compared with tga20 mice. Wild-
type mice showed clinical signs for a longer period of time, up
to 20 days for ME7 and 28 days for RML, and progressed
through each sign more slowly than tga20 mice. In the late
stages of disease CD-1 mice with RML appeared to adopt a
frozen posture, but unlike C57BL/6 inoculated with ME7, they
did not display incontinence.
Subclinical disease in tga20 mice. Mice inoculated with
those doses of either ME7- or RML-infected brain homoge-
nate which induced terminal disease showed a clear progres-
sion from early to late clinical signs. The onset of ataxia ap-
peared to determine the outcome of the infection. Mice which
displayed this particular neurological condition invariably pro-
gressed to terminal disease in an irreversible manner. Interest-
TABLE 1. ME7- or RML-induced clinical signs in tga20 mice
following intracerebral inoculation
Disease category and
clinical signsa
% of group showing signs
with the following
prion inoculum:
ME7 RML
Subclinical diseaseb
Dull, ruffled coat 100 100
Hyperactive 50 100
Kyphosis, high stepping gait 100 100
Straight tail 100 100
Head tilt 10 100
Terminal diseasec
Proprioceptive deficits 100 100
Listless, lethargic 100 100
C-shaped tail 60 100
Blank stare 100 100
Progressive ataxia 100 100
Rolling gait 40 100
Pruritus 0 40
a Clinical signs used to assess the appearance of ME7- or RML-induced
terminal mouse prion disease are shown. Following intracerebral inoculation
with prion-infected brain homogenate, mice displayed a variety of clinical signs.
These signs are listed in order of appearance from early mild signs to more
severe signs associated with terminal disease.
b Subclinical disease represents clinical signs that did not always lead to ter-
minal disease. Mice oscillated between having these signs and no signs at all.
c Terminal disease represents clinical signs that always progressed to eutha-
nasia.
TABLE 2. Comparison of ME7 and RML titrations in tga20 micea
Dilution
No. of mice succumbing to terminal disease/no. in group
(mean days to terminal disease  SD) with
the following prion inoculumb
ME7a ME7b RML 4.1 RML 5.0
101 5/5 (81  0) 5/5 (74  1) 5/5 (59  3) 5/5 (58  1)
102 5/5 (88  2) 5/5 (86  1) 5/5 (62  1) 5/5 (61  1)
103 5/5 (110 1) 5/5 (92  3) 5/5 (68  2) 5/5 (67  2)
104 5/5 (112 1) 5/5 (96  8) 5/5 (70  1) 5/5 (72  1)
105 1/5 (129 0) 5/5 (108  2) 5/5 (73  4) 5/5 (80  1)
106 0/5 (200) 5/5 (142  11) 5/5 (83 1) 5/5 (82  1)
107 0/5 (200) 1/5 (141) 5/5 (85  5) 5/5 (92  3)
108 NDc ND 0/5 (522) 1/5 (89)
109 ND ND ND 1/5 (100)
a tga20 mice were inoculated by the intracerebral route with serial 10-fold
dilutions from a 10% (wt/vol) ME7 or RML brain homogenate in a 20-l
volume. Inoculated mice were monitored daily for clinical signs of mouse prion
disease. The diagnosis of prion disease was based upon that described in Table
1. Mice were euthanized at the point of neurological disease and dysfunction.
b The infectivity titers of the inocula (calculated using the statistical method of
Karber [25]) were 106.4, 108.4, 109.2, and 109.6 LD50/g of brain for ME7a, ME7b,
RML 4.1, and RML 5.0, respectively. ME7a was acquired from the TSE Re-
source Centre, IAH, Compton, United Kingdom (supplied by the Neuropatho-
genesis Unit, Edinburgh, United Kingdom). ME7b was prepared at the Centre
for Veterinary Science from terminally sick mice previously inoculated with
ME7a.
c ND, not done.
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ingly, while mice inoculated with low doses of either ME7 or
RML inoculum failed to develop terminal disease, they did
show some early clinical signs. Surprisingly, these early signs of
disease in tga20 mice did not represent a static situation but
rather represented a transient phenomenon. Animals oscil-
lated between normal appearance and behavior and the display
of early prion disease but failed to develop ataxia. We rea-
soned that these mice with subclinical disease may have har-
bored infectious prions, as seen in other cases of subclinical
prion disease (19, 23). To assess this, brain homogenates were
prepared from mice with subclinical disease sacrificed at 200
days postinoculation and were subsequently passaged in tga20
mice to determine infectivity titers. The results are shown in
Table 4. Intriguingly, brain homogenates from those mice with
subclinical prion disease, at least in the case of ME7, appeared
to contain as much infectivity as brain homogenates prepared
from those animals which had succumbed to terminal prion
disease, as shown by the data in Table 4. The appearance of
infectivity in brain homogenates from mice with subclinical
disease is not simply due to inoculating tga20 mice with brain
homogenates. tga20 mice inoculated with uninfected CD-1 or
C57BL/6 mouse brain homogenate did not succumb to prion
disease, as shown in Table 5. Importantly, brain homogenates
from these control mice failed to induce clinical signs of dis-
ease following subsequent transmission into additional tga20
mice. This argues against the view that infectivity in mice with
subclinical disease represented merely a tga20-to-tga20 trans-
mission phenomenon.
Vacuolation and GFAP staining. Following formic acid in-
activation and paraffin embedding, brain sections were stained
with hematoxylin-eosin and with antibodies to GFAP (Fig. 2).
Figure 2 shows that gliosis (a nonspecific but early indicator of
brain damage) was detected in various brain areas surrounding
scrapie microcavities. All mice terminally sick with scrapie
displayed vacuolar changes and strong reactive gliosis with a
distinct regional profile that was specific to ME7 or RML.
Interestingly, comparing RML and ME7, which originate from
scrapied sheep brain (4, 11) and spleen (5), respectively, we
observed different pathologies in transgenic mice overexpress-
ing mouse PrP but not in wild-type mice. It was surprising to
see no difference in the pattern of pathology between ME7 and
RML in wild-type mice. RML is regarded as similar to the
mouse prion strain 139A. Both are derived from the Chandler
FIG. 1. Regression analysis of ME7 and RML incubation times. The incubation times for different preparations of RML and ME7 in tga20 mice
were plotted as a best-fit curve as described by Prusiner et al. (36). Regression analysis equations using the data from Table 2 were calculated using
the least-squares method as described by Prusiner et al. (36). ME7a, ME7 acquired from the TSE Resource Centre, IAH, Compton, United
Kingdom (supplied by the Neuropathogenesis Unit, Edinburgh, United Kingdom). ME7b, ME7 prepared at the Centre for Veterinary Science
from terminally sick mice previously inoculated with ME7a. For incubation times, n  10; for regression analysis, n  5.
TABLE 3. Mean incubation times for ME7- or RML-induced
mouse scrapie following intracerebral inoculation
into tga20, CD-1, or C57BL/6 micea
Mouse strain
Incubation time (days, mean  SD) with
the following prion inoculum:
ME7a RML 4.1
tga20 78  2 59 3
CD-1 NDb 134  3
C57BL/6 160  5 145 7
a Female tga20 or nontransgenic wild-type mice (n  10) were inoculated by
the intracerebral route with 20 l of a 101 dilution of a 10% (wt/vol) ME7 or
RML brain homogenate. Inoculated mice were monitored daily for clinical signs
of mouse prion disease. The diagnosis of prion disease was according to that
described in Table 1. Mice were euthanized at the point of neurological disease
and dysfunction. ME7a, ME7 acquired from the TSE Resource Centre, IAH,
Compton, United Kingdom (supplied by the Neuropathogenesis Unit, Edin-
burgh, United Kingdom).
b ND, not done.
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strain, and profound differences between ME7 and 139A le-
sion profiles in wild-type mice are reported (17).
Detection of PrPSc in animals with subclinical disease.
PrPSc was detected in brain stems from tga20 mice that had
succumbed to terminal prion disease and was also seen in
samples from mice exhibiting subclinical disease, as shown in
Fig. 3. ME7 and RML brain stem homogenates from tga20
mice with subclinical disease showed different susceptibilities
to PK digestion, and each could be satisfactorily digested only
in separate buffers. RML PrPSc was most sensitive to PK treat-
ment in homogenate buffer, whereas ME7 was digested only in
lysis buffer. This differential susceptibility to PK digestion in
different buffers was maintained for brain homogenates from
wild-type mice that had succumbed to terminal prion disease,
and like tga20 mice, all showed the presence of PrPSc. Al-
though it was not formally quantified, more PrPSc appeared to
be present in samples of ME7-inoculated brain tissue than in
RML-inoculated samples.
DISCUSSION
The agent responsible for prion disease may exist in different
forms, each carrying the specific information which determines
its own distinct biological properties, such as incubation pe-
riod, lesion profile, and PrPSc glycoform pattern. The protein-
only hypothesis predicts that variation between different prion
inocula, including those from the same species, is enciphered
in the different conformations which may be taken up by PrPSc.
Here we have compared the transmission characteristics of the
mouse prion inocula ME7 and RML in tga20 mice. Both of
these inocula are derived from natural sheep scrapie material,
although each originates from a different tissue site. RML is
from the scrapied brain homogenate SSBP/1 after transmission
to goats and is passaged in CD-1 mice (8). In contrast, the ME7
inoculum was isolated by passage of scrapied sheep spleen
tissue in RIII mice (a subline of the C57BL/6 strain) (13, 14,
40).
Different transmission characteristics are evident for ME7
and RML in tga20 mice. RML induced the most rapid onset of
terminal disease, which was reached after only 58 days of
incubation following inoculation with a high dose of inoculum
injected by the intracerebral route. In contrast, the highest
dose of ME7 induced terminal disease after 74 days. These
incubation times are considerably shorter, by approximately
50%, than those seen in the wild-type mice used to routinely
passage these inocula. The differences in incubation times be-
tween ME7 and RML in tga20 mice was maintained between
different preparations of each inoculum as seen by the com-
parison of regression analysis lines. On each occasion tested,
the RML inoculum showed a higher titer than ME7, and our
titer values are consistent with those seen by others. The RML
inoculum routinely displays a titer of 109.5 50% lethal doses
(LD50)/g of brain in tga20 mice (M. A. Klein and A. Aguzzi,
unpublished data), while ME7 has a titer of 108 (39) in
C57BL/6 mice. Collectively, our transmission studies show that
tga20 mice can successfully be used to assess both ME7 and
RML infectivities and that these different inocula induce ter-
minal disease with a distinct set of clinical signs. Histological
examination of brain sections from prion-inoculated tga20
mice with terminal disease revealed that ME7 caused a more
general and extensive pattern of vacuolation than RML.
In experimentally inoculated mice, the onset of terminal
disease is usually signaled by the appearance of early mild
clinical signs, such as head shaking or excitability, which
progress to late-stage signs, such as proprioceptive defects and
severe ataxia. All of the mice inoculated in this study which
developed ataxia invariably succumbed to terminal prion dis-
ease. However, careful observation of inoculated mice identi-
fied those which developed intermittent mild signs of disease
but did not progress to ataxia. These mice had received a low
dose of inoculum. Intermittent or reversible clinical signs in
TABLE 4. Prion infectivity in the central nervous systems of
mice with subclinical ME7- or RML-induced diseasea
Inoculumb Dilutionc
No. of mice
succumbing to
terminal disease/no.
of mice in group
Mean days to
terminal dis-
ease  SD
Titer
(LD50/g
of brain)d
ME7a 104 (terminal) 5/5 84  4 105.1
5/5 83  4
105 (terminal) 5/5 79  0 105.5
5/5 79  1
106 (subclinical) 5/5 87  1 104.8
5/5 87  1
107 (subclinical) 5/5 82  4 104.7
5/5 95  2
RML 5.0 106 (terminal) 5/5 73  3 105.1
5/5 78  4
107 (terminal) 5/5 82  0 104.9
5/5 72  1
108 (subclinical) 5/5 88  1 102.9
5/5 87  1
109 (subclinical) 4/5 130  4 1
3/5 127  0
a Twenty-microliter volumes of 10% (wt/vol) brain homogenates prepared
from tga20 mice that had succumbed to terminal prion disease or from mice with
subclinical disease that were euthanized at 200 days after prion inoculation
were inoculated by the intracerebral route into tga20 mice. Inoculated mice were
monitored daily for clinical signs of mouse prion disease. The diagnosis of prion
disease was based upon that described in Table 1. Mice were euthanized at the
point of neurological disease and dysfunction.
b ME7a, ME7 acquired from the TSE Resource Centre, IAH, Compton,
United Kingdom (supplied by the Neuropathogenesis Unit, Edinburgh, United
Kingdom).
c The dilutions listed represent those inoculated into the primary mice accord-
ing to Table 2.
d Prion titers were calculated according to the formulae described in Figure 1.
TABLE 5. Control brain homogenates inoculated by the
intracerebral route into tga20 micea
Homogenate
No. of mice succumbing to
terminal disease/no. of
mice in group
Incubation time
(days postinoc-
ulation)
tga20b 0/5 309
C57BL/6 0/5 612
CD-1 0/5 612
tga20-passaged C57BL/6c 0/5 295
tga20-passaged CD-1 0/5 295
a Brain homogenates (20 l per mouse, 10% [wt/vol]) prepared from unin-
fected tga20, C57BL/6, or CD-1 mice were inoculated by the intracerebral route
into tga20 mice. The tga20 mice previously inoculated with uninfected C57BL/6
or CD-1 brain homogenates were sacrificed at 300 days post inoculation, and
10% (wt/vol) brain homogenates were passaged into further tga20 recipients. All
mice were monitored daily and did not show any clinical signs.
b Original brain material used to inoculate tga20 recipients.
c Second-passage brain material.
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wild-type mice inoculated with low doses of ME7 have been
described before (39). Here we report a similar finding follow-
ing inoculation of tga20 mice with an ME7 or RML prion
inoculum. However, in contrast to the study by Taylor et al.
(39), where the oscillating clinical signs culminated in terminal
disease, in the experiments reported here, the oscillating clin-
ical signs have not reached terminal disease. Transmission of
brain homogenates prepared from ME7- or RML-inoculated
tga20 mice with subclinical disease induced terminal disease in
additional tga20 mice and with incubation times similar to
those for brain homogenates from mice with terminal disease.
The level of infectivity in subclinical ME7 brain homogenates
was 105 LD50/g of brain in both groups of mice tested, and
this value was similar to that from mice that succumbed to
terminal disease. All of these prion titers were significantly
greater than the amount inoculated. A similar trend was seen
following RML inoculation, although the amount of infectivity
associated with subclinical brain homogenates titrated out in
the dilutions tested. The failure of uninfected tga20 brain ho-
mogenate to cause any disease after inoculation into additional
tga20 mice implies that the infectivity in animals with subclin-
ical disease does represent authentic prion accumulation.
There are further examples in the literature of chronic sub-
clinical infections with prions. Mice heterozygous for PrP gene
disruption show high prion and PrPSc levels but a delayed
onset of disease (7), immunodeficient mice do not succumb to
disease despite high levels of prions and PrPSc (19), and ham-
ster prions can persist (37) and replicate (23) in mice in a
clinically silent fashion. In all of these studies infectivity in
animals with subclinical disease was seen after inoculation with
relatively high doses of inoculum. The intriguing feature of the
subclinical disease infectivity reported here is that it was in-
FIG. 2. Histology and immunocytochemistry. Sections of brain tissue were subjected to conventional staining with hematoxylin and eosin (rows
1 and 3) and examined histologically to confirm prion pathology by the presence of microvacuolation. Reactive gliosis was confirmed by
immunohistochemistry for glial fibrillary acidic protein (rows 2 and 4). Magnification, 250.
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duced by dilutions of inoculum that were below the end point
of titration.
A second feature of our findings was the detection of PrPSc
in the brains of tga20 mice with subclinical prion disease.
When we assessed the levels of PrPSc in whole brain homog-
enates from the tga20 mice, we could detect only small
amounts in the group with subclinical disease inoculated with
RML at a dilution of 109 and in both groups with subclinical
disease inoculated with ME7 (data not shown). We were rou-
tinely unable to detect significant levels of PrPSc in whole brain
homogenates from the terminally sick mice for both prion
strains. However, when we tested brain stem samples only, we
were able to detect PrPSc in all groups of mice, as shown in Fig.
3. Unlike in tga20 mice, PrPSc was detectable in the whole
brain homogenates of wild-type animals, which express normal
levels of PrPc. Other reports have shown that while tga20 mice
can succumb to terminal disease after a very short incubation
time, PrPSc in whole brain homogenates was present at low
levels (16); in our case it was undetectable when assessed by
Western blotting. Several possibilities exist for this apparent
lack of, or small amounts of, PrPSc in tga20 mice with terminal
disease. First, disease may occur rapidly in tga20 mice prior to
appreciable accumulation of PrPSc in regions of the brain other
than the brain stem. Second, the resultant PrPSc may be highly
sensitive to PK digestion, giving the impression that there is
little, if any, of this form of PrP, as reported for other examples
of prion disease (9, 24, 29, 30). In this respect, it is interesting
that brain homogenates from tga20 mice inoculated via the
sciatic nerve (20), which were associated with terminal disease
incubation times of up to 90 days, did not show much if any
PrPSc. It is possible that the higher levels of PrPSc which ac-
cumulate in the tga20 mice with subclinical disease do so as a
consequence of the extended duration of the disease process.
A third reason for lack of appreciable PrPSc formation in tga20
mice when whole brain homogenates were assessed is that the
transgenic nature of PrP in these mice may render this material
inherently unstable and/or readily metabolized. Although ME7
and RML required different buffers for efficient PK cleavage to
detect PrPSc, the same buffer was effective for brain tissue from
both tga20 mice with subclinical disease and wild-type mice
with terminal disease. This suggests that ME7 and RML PrPSc
retains some conformational similarity, and therefore stability,
when expressed in the different mouse strains.
The accumulation of PrPSc is the only established by-product
of prion disease, and its detection is routinely used for bio-
chemical diagnosis of transmissible spongiform encephalopa-
thies (26). Molecular analysis of PrPSc through quantitative
assessment of the ratios of the different glycoforms and mo-
lecular mass measurement of unglycosylated proteins have
been used to distinguish different prion inocula (2, 6, 10).
However, while the PK and Western blot procedure is sug-
gested to be of comparable sensitivity to heterologous bioassay
for BSE or CJD material in mice, the test is essentially non-
quantitative and difficult to standardize. A critical feature of
the assay is the concentration of PK used. If the concentration
of PK used is too high, the enzyme may remove small quanti-
ties of PrPSc. Conversely, too low a concentration of enzyme
may not remove all of the relatively large amount of PrPc.
Other markers of prion disease are required. Barnard et al. (1)
have described a sensitive time-fluorescence immunoassay
FIG. 3. Western blot analysis of PrPSc in brain stem homogenates from ME7- or RML-infected mice with terminal and subclinical disease.
Aliquots of 10% (wt/vol) brain stem homogenates prepared from ME7- or RML-inoculated mice were treated with PK, followed by Western
blotting with XN polyclonal anti-mouse PrP serum and enhanced chemiluminescence. Ten microliters for non-PK-treated samples and 15 l for
PK-treated samples (equivalent to 40 to 50 g of total protein) were loaded. The left-hand panels show the positive control sample from wild-type
mice inoculated with a 101 dilution. ME7 (TSE Resource Centre) and RML 5.0 terminal and subclinical brain stem homogenates are shown.
Numbers on the left are molecular masses in kilodaltons.
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which distinguishes normal cattle from BSE-infected cattle by
measurement of insoluble PrP, which increases during disease.
Miele et al. (31) have reported that erythroid differentiation-
related factor (EDRF) is decreased in spleen tissue and bone
marrow of ME7-inoculated mice with terminal disease. Signif-
icantly, levels of EDRF mRNA were decreased well in advance
of any clinical signs. Analysis of either insoluble PrP or EDRF
RNA may aid the diagnosis of subclinical prion disease.
Collectively, our observations with tga20 mice suggest that
events other than merely prion infectivity and PrPSc accumu-
lation are responsible for triggering terminal prion disease.
Our data also suggest that susceptibility to prion disease should
not be judged solely by the development of terminal clinical
signs. It is presently unknown if subclinical prion disease exists
within individuals, either human or animal, with natural trans-
missible spongiform encephalopathies, and this is an important
point to elucidate. Our data, here using same-species transmis-
sion, show that high levels of infectivity can accumulate within
infected mice following exposure to extremely low doses of
inoculum. It will be important to carry out similar low-dose
prion transmission studies using xenogeneic inocula to assess
the risks associated with cross-species prion infectivity. These
data may have important implications for public health regard-
ing iatrogenic transmission of variant CJD from apparently
healthy individuals previously exposed to BSE-contaminated
bovine products.
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